Evidence for antibody-mediated injury as a Major determinant of late kidney allograft failure

Transplantation

Volumn 90, Issue 1, 2010, Pages 68-74

  Gaston, Robert S ^a   Cecka, J Michael ^b   Kasiske, Bert L ^c   Fieberg, Ann M ^d   Leduc, Robert ^d   Cosio, Fernando C ^e   Gourishankar, Sita ^f   Grande, Joseph ^e   Halloran, Philip ^f   Hunsicker, Lawrence ^g   Mannon, Roslyn ^a   Rush, David ^h   Matas, Arthur J ⁱ  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF IOWA HEALTH CARE   (United States)

^h HEALTH SCIENCES CENTRE   (Canada)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Chronic rejection; Donor specific antibody.; Immunosuppression; Kidney transplant

Indexed keywords

ANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CREATININE; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANTIBODY MEDIATED INJURY; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HUMAN; INFLAMMATION; INJURY; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; STAINING;

ADULT; BIOPSY; COMPLEMENT C4B; CREATININE; ETHNIC GROUPS; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 77954623148     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e065de     Document Type: Article

References (31)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies Am J Transplant 2004; 4: 1289.
2. United States Renal Data System. USRDS 2008 Annual Data Report. Available at: www.usrds.org. Accessed November 8, 2009.
3. Solez K, Colvin RB, Racusen LC, et al. Banff 05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
4. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
5. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346:580.
6. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
7. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the "troubled transplant": Data from the DeKAF study. Am JTransplant 2010; [Epub ahead of print].
8. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups owithin the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study. Am J Transplant 2009; [Epub ahead of print].
9. Grande J, Matas A, Kasiske B, et al. C4d deposition as a marker of adverse long term renal allograft outcome (abstract). Am J Transplant 2009; 9(suppl 2): 583.
10. Bocrie O, Hussein Aly AA, Guignier F, et al. Distribution of donor-specific antibodies in the cortex and the medulla of renal transplants with chronic allograft nephropathy. Transpl Immunol 2007; 17: 227.
11. IssaN, CosioFG, Gloor JM, et al. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681.
12. Hidalgo LG, Campbell PM, Sis B, et al. Denovo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
13. Kieran N, Wang X, Perkins J, et al. Combination ofperitubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 2009; 20: 2260.
14. Martin L, Charon-Barra C, Bocrie O, et al. Detection of plasma cells, C4d deposits and donor-specific antibodieson sequential graft biopsies of renal transplant recipients with chronic dysfunction. Transpl Immunol 2010; 22: 110.
15. Jeannet M, Pinn VW, Flax MH, et al. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970; 282: 111.
16. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331: 365.
17. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: Apotentially adverse responsetorenal ablation.Am J Physiol 1981; 241: F85.
18. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377.
19. El Kossi M, Harmer A, Goodwin J, et al. De novo membranous ne-phropathy associated with donor-specific alloantibody. Clin Transplant 2008; 22: 124.
20. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371.
21. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125.
22. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
23. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: Follow-up study. J Am Soc Nephrol 2002; 13: 2962.
24. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
25. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotox-icity. Clin J Am Soc Nephrol 2009; 4: 481.
26. Snanoudj R, Royal V, Timsit M-O, et al. Comparison of histological lesions on ten year protocol biopsies in kidney transplant recipients with or without cyclosporine (abstract). Am J Transplant 2009; 9(suppl 2): 200.
27. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
28. Mengel M, Reeve J, Bunnag S, et al. Molecular correlates of scarring in kidney transplants: The emergenceofmast cell transcripts. Am JTrans-plant 2009; 9: 169.
29. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747.
30. Zarkhin V, Kambham N, Li L, et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008; 74: 664.
31. Lerut E, Kuypers DR, Verbeken E, et al. Acute rejection in non-compliant renal allograft recipients: A distinct morphology. Clin Transplant 2007; 21: 344.